Strong Q1 beat with accelerating CARVYKTI sales growth (62% YoY) and clear path to profitability with adjusted net loss narrowing to just $10.5M. The $55M milestone from European approvals adds Q2 revenue. Watch for continued margin improvement as manufacturing scale increases and for pipeline data readouts at upcoming medical conferences.
Price Chart
Executive Summary
Legend Biotech reported Q1 2026 results with total revenue of $305.1M, up 56% YoY from $195.0M, driven by a 61% increase in collaboration revenue from CARVYKTI sales to $298.4M. Net loss narrowed to $54.3M from $101.0M YoY, primarily due to lower unrealized FX losses. CARVYKTI net trade sales grew 62% YoY to ~$597M, and the company achieved $55M in milestones in April 2026.
Key Facts
- Total revenue of $305.1M for Q1 2026, up 56% from $195.0M in Q1 2025
- Collaboration revenue from CARVYKTI was $298.4M, up 61% from $185.6M YoY
- CARVYKTI net trade sales increased 62% YoY to approximately $597M
- Net loss narrowed to $54.3M from $101.0M YoY, a 46% improvement
- Adjusted net loss improved to $10.5M from $27.0M YoY
- Cash and cash equivalents plus time deposits of $834.6M as of March 31, 2026
- Achieved $55M in milestones in April 2026 from European commercialization approvals
- Operating loss improved to $49.8M from $51.7M YoY
- Cost of collaboration revenue increased to $175.4M from $69.5M YoY due to capacity expansion
- CARVYKTI now available in 18 global markets with 99% manufacturing success rate
Financial Impact
Revenue growth of $110.1M YoY (56%), net loss reduction of $46.7M YoY (46%), and $55M milestone payments in April 2026
Risk Factors
- Cost of collaboration revenue grew faster than collaboration revenue (152% vs 61% YoY), pressuring gross margins
- Cash burn remains significant with $85.1M used in operations and $168M in investing activities in Q1
- Dependence on CARVYKTI as sole approved product with no other near-term catalysts
- Potential future tariffs on pharmaceutical imports could impact costs despite domestic US production
- Collaboration interest-bearing advanced funding of $266M classified as current liability due within 12 months
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001801198-26-000014 |
| Document: a991earningsreleaseq12026.htm | 0001801198-26-000014 |
| Document: q126pipeline.htm | 0001801198-26-000014 |
| Document: 0001801198-26-000014-index-headers.html | 0001801198-26-000014 |
| Document: 0001801198-26-000014-index.html | 0001801198-26-000014 |
| Document: 0001801198-26-000014.txt | 0001801198-26-000014 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers